This work describes the synthesis and characterization of the 11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazoles analogous to LQB223, a previously synthesized compound by our research group that has anti-cancer and antileishmanial activity in vitro and antimalarial activity in vitro and in vivo. The key step of the reaction for obtaining the 5-methoxy-11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazole (97a), 6-methoxy-11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazole (97b) and 7-methoxy-11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazole (97c) is the palladium catalyzed Heck aza-arylation reaction in the presence of silver carbonate and acetone from N-tosyl-o-iodoaniline (55b) and substituted dihydronaphthalenes (100a, 100b and 100c), previously prepared from commercial tetralones (84a, 84b and 84c). The compounds 5-hydroxy-11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazole (98a), 6-hydroxy-11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazole (98b) and 7-hydroxy-11a-N-arylsulfonil-tetrahydro-5H-benzo[a]carbazole (98c) were obtained by deprotection with BBr3 in yields quantitative. All compounds were evaluated for anticancer activity in K562, FEPS and Lucena leukemia cell lines, which exhibit the MDR phenotype, and in breast cancer cell lines MCF-7, which expresses the estrogen receptor, and MDA-MD231.Among the compounds prepared, the compound 97b is as active as LQB223 for the antileukemic activity on K562 lines, and Lucena FEPs, however it is more effective than the LQB223 in MCF-7 (IC50 equal 5.93 plus/minus 3.58 MiM) and MDA-MD231 (IC50 equal 8.29 plus/minus 2.08 uM) breast cancer lines, with low level of toxicity to healthy cells. The compound 98b presents similar activity to 97b but is toxic. The compound 98c is effective in MDA-MD231 (IC50 equal 4,84) but, level of toxicity to healthy cells was not test yet. The reports suggest that the oxygenation pattern in the 3 position directs to the anticancer activity to the breast cancer lines.